The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Official Title: A Phase I/II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Study ID: NCT05789589
Brief Summary: To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Name: Minesh Mehta, M.D.
Affiliation: Miami Cancer Institute at Baptist Health, Inc.
Role: PRINCIPAL_INVESTIGATOR
Name: Yazmin Odia, M.D.
Affiliation: Miami Cancer Institute at Baptist Health, Inc.
Role: PRINCIPAL_INVESTIGATOR